

SUPPORTING INFORMATION

Stereodivergent access to all four stereoisomers of chiral tetrahydrobenzo[*f*][1,4]oxazepines, through highly diastereoselective multicomponent Ugi-Joullié reaction.

Alessandro Pinna,^a Andrea Basso,^a Chiara Lambruschini,^a Lisa Moni,^a Renata Riva,^b Valeria Rocca, and Luca Banfi^{a*}

^a Department of Chemistry and Industrial Chemistry, Università di Genova, via Dodecaneso, 31, 16146 GENOVA, Italy. [tel.: +39 0103536111; fax: +39 0103536117; E-mail: banfi@chimica.unige.it]

^b Department of Pharmacy, Università di Genova, viale Cembrano 4, 16147 GENOVA, Italy.

Table of contents


Experimental procedures	p. S2
HPLC determination of enantiomeric excesses and diastereomeric ratios.....	p. S17
Conformational analysis of compounds 13 and 14	p. S25
Conformational analysis of imine 3e	p. S28
Conformational analysis of amides 10j-11j.....	p. S29
¹ H and ¹³ C NMR spectra of all new compounds.....	p. S31

Experimental procedures

General methods

NMR spectra were taken at the indicated temperature in CDCl₃ or d₆-DMSO at 300 MHz (¹H), and 75 MHz (¹³C), using, as internal standard, TMS (¹H NMR: 0.000 ppm) or the central peak of CDCl₃ (¹³C: 77.02 ppm), or the central peak of DMSO (¹H NMR in d₆-DMSO; 2.506 ppm), or the central peak of DMSO (¹³C in d₆-DMSO; 39.43 ppm). Chemical shifts are reported in ppm (δ scale). Peak assignments were made with the aid of gCOSY and gHSQC experiments. HRMS: samples were analysed with a Synapt G2 QToF mass spectrometer. MS signals were acquired from 50 to 1200 m/z in ESI positive ionization mode. TLC analyses were carried out on silica gel plates and viewed at UV (254 nm) and developed with Hanessian stain (dipping into a solution of (NH₄)₄MoO₄·4 H₂O (21 g) and Ce(SO₄)₂·4 H₂O (1 g) in H₂SO₄ (31 ml) and H₂O (469 ml) and warming) or with ninhydrin. R_f were measured after an elution of 7-9 cm. Column chromatographies were done with the "flash" methodology using 220-400 mesh silica. Petroleum ether (40-60 °C) is abbreviated as PE. In extractive work-up, aqueous solutions were always reextracted three times with the appropriate organic solvent. Organic extracts were always dried over Na₂SO₄ and filtered, before evaporation of the solvent under reduced pressure. All reactions using dry solvents were carried out under a nitrogen atmosphere.

General procedure for the synthesis of Boc-protected amino alcohols 7a-c from the corresponding Boc-α-amino acids.




Boc-amino acid was dissolved in dry THF (1 mL/mmol). This solution was cooled at -10 °C, and isobutyl chloroformate (1.2 eq.) and N,N-diisopropylethylamine (1.5 eq.) were added in this order. The mixture was stirred at -10 °C for 1h. Then it was filtered and the filtrate was cooled at -10 °C and treated with NaBH₄ (1.5 eq.) and H₂O (3 mL/mmol of NaBH₄), in this sequence. After stirring at -10 °C for 30 min and at rt for 1h, the mixture was diluted with AcOEt and with saturated aqueous NH₄Cl and 5% aqueous (NH₄)₂HPO₄/NH₄ (resulting pH = 5). After phase separation, the organic phases were washed with brine, and evaporated to dryness. Chromatography afforded the pure products.

7a. Chromatography: PE/AcOEt/CH₂Cl₂ 2:1:2. Yield: 88%. Only (*S*)-compound was prepared and used. This compound is known.¹

7b. Chromatography: PE/AcOEt/CH₂Cl₂ 1:1:1. Yield: 87%. Only (*S*)-compound was prepared and used. This compound is known.²

7c. Chromatography: PE/AcOEt 3:1. Yield: 87%. Only (*S*)-compound was prepared and used. This compound is known.²

General procedure for the synthesis of Boc-protected amino alcohols 7d-e from the corresponding amino alcohol.




1.010 g (7.36 mmol) of R-(-)-2-phenyl glycinol was dissolved in 12.3 mL of dry CH₂Cl₂. 1.13 mL (8.11 mmol, 1.1 eq.) of Et₃N and 1.771 g (8.11 mmol, 1.1 eq.) of (Boc)₂O were added at this solution. The mixture was stirred overnight at room temperature, then it was diluted with CH₂Cl₂ and with 1 M HCl. After phase separation, the organic phases were washed with saturated aqueous NaHCO₃, and evaporated to dryness. The crude product was purified by chromatography using PE:AcOEt:CH₂Cl₂ 2:1:1. The product (1.500 g, 6.32 mmol) was obtained as a white solid with a yield of 86,0%. This product is known.³

Using the same procedure, both (*R*)- and (*S*)-**7e** were prepared in 93% yield from the corresponding amino alcohols. They are both known.²

Optimization of the Mitsunobu reaction to give 8a


The reaction was first optimized using stoichiometric quantities of the two reagents. Thus, all the following reactions were carried out in THF at 0°C for 3 h and then at rt overnight, using 1 eq. each of **6a** and **7a** and 1.5 eq. of PPh₃ and of azodicarboxylate. A main side-product was detected, corresponding to Boc-aziridine **9a**.



Azodicarboxylate	Isolated yield of 8a (from 1a)	Isolated yield of 9a (from 1a)
Di-tert-butyl azodicarboxylate (TBAD)	25%	54%
Diethyl azodicarboxylate (DEAD)	45%	31%
Diisopropyl azodicarboxylate (DIAD)	31%	44%
1,1'-(Azodicarbonyl)dipiperidine (ADDP)	72%	12%

Then, also taking into account the fact that the Boc-amino alcohol is more precious than the salicylaldehyde, we decided to use a slight excess (1.2 equiv.) of salicylaldehyde. Finally, we noticed that a slight better yield was achieved by adding PPh₃ and azodicarboxylate in three portions.

Typical procedure for the Mitsunobu reaction. (S)-tert-Butyl (1-(2-(dimethoxymethyl)phenoxy)-3-phenylpropan-2-yl)carbamate **8a**.




A solution of salicylaldehyde (0.770 mL, 901 mg, 7.38 mmol) in dry MeOH (8.1 mL) was treated with trimethyl orthoformate (3.50 mL, 32.0 mmol) and Amberlyst 15 (100 mg). The resulting mixture was stirred at room temperature for 20 h, then diluted with CH₂Cl₂ and filtered. The filtrate was treated with solid NaHCO₃ (25 mg) and filtered again. The filtrate was evaporated, and the residue was taken up in CH₂Cl₂/toluene, and again evaporated to azeotropically remove all methanol. The crude acetal **6a** was obtained as a yellow oil (1.380 g). This acetal (301.7 mg, theoretical 1.61 mmol, 1.2 equiv.)

was dissolved in dry THF (2.60 mL), cooled to 0°C, and treated sequentially with Boc-amino alcohol **7a** (330.5 mg, 1.31 mmol, 1 equiv.), PPh₃ (171.8 mg, 0.655 mmol, 0.5 equiv.) and 1,1'-(Azodicarbonyl)dipiperidine (ADDP) (165.5 mg, 0.656 mmol, 0.5 equiv.). After stirring at 0°C for 60 min, further PPh₃ (171.8 mg, 0.655 mmol) and ADDP (165.5 mg, 0.656 mmol) were added. Finally, after 60 minutes, an identical amount of both reagents was added. The mixture was further stirred overnight at rt and evaporated to dryness. The crude was taken up in Et₂O and washed with 1 M NaOH, to remove excess of **6a**. The organic phase was washed with aqueous saturated NH₄Cl, evaporated and purified by chromatography (PE / AcOEt 11:1) to give pure **8a** as an oil (411.4 mg, 78% from **7a**).


R_f = 0.20 (PE / AcOEt 10:1). $[\alpha]_D^{25} = -15.1$ (c 1.1, CHCl₃). ¹H NMR (300 MHz, CDCl₃, 20 °C): δ = 7.54 (1 H, dd, J = 7.6, 1.6 Hz), 7.34-7.14 (6 H, m), 6.98 (1 H, t, J = 7.5 Hz), 6.76 (1 H, d, J = 8.2 Hz), 5.73 (1 H, s, CH(OCH₃)₂), 5.63 (1 H, broad d, J = 8.1 Hz, NH), 4.21-4.05 (1 H, broad m, CHN), 3.98 (1 H, dd, J = 9.3, 2.6 Hz, CHHO), 3.84 (1 H, dd, J = 9.3, 3.8 Hz, CHHO), 3.47 (3 H, s, OCH₃), 3.29 (3 H, s, OCH₃), 3.10-2.94 (2 H, m, CH₂Ph), 1.43 (9 H, s, C(CH₃)₃). ¹³C NMR (75 MHz, CDCl₃, 20 °C): δ = 156.5, 155.5 (C=O and C-O), 138.1, 126.1 (quat.), 129.8, 129.5 (x2), 128.5 (x2), 127.6, 126.5, 120.7, 112.3 (aromatic CH), 99.4 (CH(OCH₃)₂), 79.3 (C(CH₃)₃), 68.6 (CH₂O), 54.4 (OCH₃), 51.7 (OCH₃ and CHN), 38.2 (CH₂Ph), 28.4 (C(CH₃)₃). I.R. (ATR): $\nu_{\max}$ 3346, 2978, 2930, 2897, 2827, 1700, 1606, 1590, 1522, 1494, 1455, 1442, 1388, 1365, 1337, 1284, 1244, 1203, 1164, 1125, 1096, 1047, 1033, 987, 973, 960, 921, 901, 881, 866, 850, 822, 780, 763, 742, 698, 670, 641, 623, 608 cm⁻¹. HRMS (ESI⁺): found 402.2287 [Calcd for C₂₃H₃₂NO₅⁺ (M + H)⁺ 402.2280].

(S)-tert-Butyl 2-benzylaziridine-1-carboxylate **9a**.



Oil. R_f = 0.49 (PE / AcOEt 10:1). ¹H NMR (300 MHz, CDCl₃, 20 °C): δ = 7.35-7.20 (5 H, m), 3.02-2.89 (1 H, m, CHN), 2.71-2.57 (2 H, m, CH₂N), 2.31 (1 H, d, J = 6.0 Hz, CHHPh), 2.03 (1 H, d, J = 3.6 Hz, CHHPh), 1.44 (9 H, s, C(CH₃)₃). This compound is known.⁴


(S)-tert-Butyl (1-(2-(dimethoxymethyl)phenoxy)-4-methylbutan-2-yl)carbamate **8b**.



It was prepared from salicylaldehyde and Boc-amino alcohol **7b** following the same procedure described for **8a**, but using stoichiometric quantities of **6a** and Boc-amino alcohol **7b**. The isolated yield of **8b** was 65% from salicylaldehyde. Chromatography was carried out with PE: AcOEt 30:1 → 10:1.

Oil. R_f = 0.34 (PE / AcOEt 30:1). $[\alpha]_D^{25} = +50.3$ (c 1.0, CHCl₃). ¹H NMR (300 MHz, CDCl₃, 20 °C): δ = 7.52 (1 H, dd, J = 7.5, 1.5 Hz), 7.29 (1 H, td, J = 7.8, 1.5 Hz), 6.97 (1 H, td, J = 7.5, 1.2 Hz), 6.85 (1 H, dd, J = 8.1, 0.6 Hz), 5.65 (1 H, s, CH(OCH₃)₂), 5.29 (1 H, broad d, J = 8.1 Hz, NH), 4.10-3.91 (3 H, m, CHN, CHHO), 3.43 (3 H, s, OCH₃), 3.28 (3 H, s, OCH₃), 1.80-1.45 (2 H, m, CH₂CH(CH₃)₂), 1.43 (9 H, s, C(CH₃)₃), 0.97 (6 H, d, J = 6.6 Hz, (CH₃)₂CH). ¹³C NMR (75 MHz, CDCl₃, 20 °C): δ = 156.6, 155.6 (C=O and C-O), 129.8, 127.5, 120.6, 112.2 (aromatic CH), 126.2 (quat.), 99.3 (CH(OCH₃)₂), 79.1 (C(CH₃)₃), 71.0 (CH₂O), 54.5 (OCH₃), 52.0 (OCH₃), 48.4 (CHN), 41.4 (CH₂iPr), 28.4 (C(CH₃)₃), 24.9 (CH(CH₃)₂), 22.9, 22.5 (CH(CH₃)₃). I.R. (ATR): $\nu_{\max}$ 3349, 2956, 2933, 2871, 2830, 1697, 1604, 1516, 1491, 1455, 1391, 1366, 1329, 1285, 1241, 1163, 1118, 1091, 1047, 977, 910, 872, 847, 811, 754, 731, 672, 647, 610 cm⁻¹. HRMS (ESI⁺): found 368.2429 [Calcd for C₂₀H₃₄NO₅⁺ (M + H)⁺ 368.2437].


(S)-tert-Butyl (1-(2-(dimethoxymethyl)phenoxy)-3-methylpropan-2-yl)carbamate 8c.



It was prepared from salicylaldehyde and Boc-amino alcohol **7c** following the same procedure described for **8a**, but using 1.1 equiv. of **6a** relative to Boc-amino alcohol **7c**. The isolated yield of **8c** was 55% from **7c**. Chromatography was carried out with PE: AcOEt 16:1 → 10:1.

Oil. R_f = 0.25 (PE / AcOEt 16:1). $[\alpha]_D = -56.2$ (c 1.0, CHCl_3). ^1H NMR (300 MHz, CDCl_3 , 20 °C): δ = 7.52 (1 H, dd, J = 7.6, 1.6 Hz), 7.29 (1 H, td, J = 7.5, 1.5 Hz), 6.98 (1 H, t, J = 7.5 Hz), 6.85 (1 H, d, J = 8.1 Hz), 5.64 (1 H, s, $\text{CH}(\text{OCH}_3)_2$), 5.43 (1 H, broad d, J = 9.0 Hz, NH), 4.21 (1 H, dd, J = 9.3, 2.8 Hz, CHHO), 3.92 (1 H, dd, J = 9.3, 3.8 Hz, CHHO), 3.73-3.60 (1 H, m, CHN), 3.43 (3 H, s, OCH_3), 3.26 (3 H, s, OCH_3), 2.02 (1 H, octuplet, J = 7.1 Hz, $\text{CH}(\text{CH}_3)_2$), 1.43 (9 H, s, $\text{C}(\text{CH}_3)_3$), 1.02 (3 H, d, J = 6.9 Hz, $(\text{CH}_3)\text{CH}$), 1.00 (3 H, d, J = 6.9 Hz, $(\text{CH}_3)\text{CH}$). ^{13}C NMR (75 MHz, CDCl_3 , 20 °C): δ = 156.7, 155.9 (C=O and C-O), 129.8, 127.5, 120.5, 112.1 (aromatic CH), 126.2 (quat.), 99.3 ($\text{CH}(\text{OCH}_3)_2$), 79.0 ($\text{C}(\text{CH}_3)_3$), 69.1 (CH_2O), 55.6 (CHN), 54.5 (OCH_3), 51.7 (OCH_3), 30.2 ($\text{CH}(\text{CH}_3)_2$), 28.4 ($\text{C}(\text{CH}_3)_3$), 19.6, 19.3 ($\text{CH}(\text{CH}_3)_3$). I.R. (ATR): ν_{max} 3348, 2962, 2934, 2829, 1711, 1604, 1591, 1516, 1491, 1456, 1390, 1365, 1286, 1240, 1170, 1121, 1092, 1073, 1045, 1028, 979, 946, 911, 883, 867, 807, 755, 737, 703, 675, 650, 620, 610 cm^{-1} . HRMS (ESI⁺): found 354.2284 [Calcd for $\text{C}_{19}\text{H}_{32}\text{NO}_5^+$ (M + H)⁺ 354.2280].

(R)-tert-Butyl (2-(2-(dimethoxymethyl)phenoxy)-1-phenylethan-1-yl)carbamate 8d.




It was prepared from salicylaldehyde and Boc-amino alcohol **7d** following the same procedure described for **8a**, but using 1.1 equiv. of **6a** relative to Boc-amino alcohol **7d**. The isolated yield of **8d** was 42% from **7c**. Chromatography was carried out with PE: AcOEt 8:1 → 6:1.

Oil. R_f = 0.20 (PE / AcOEt 8:1). $[\alpha]_D = -33.5$ (c 1.2, CHCl_3). ^1H NMR (300 MHz, CDCl_3 , 20 °C): δ = 7.49 (1 H, dd, J = 7.6, 1.6 Hz), 7.46-7.22 (6 H, m), 6.97 (1 H, t, J = 7.5 Hz), 6.82 (1 H, d, J = 8.4 Hz), 6.12 (broad s, NH), 5.54 (1 H, s, $\text{CH}(\text{OCH}_3)_2$), 5.09 (1 H, broad s, CHNH), 4.32-4.15 (2 H, m, CH_2O), 3.40 (3 H, s, OCH_3), 3.28 (3 H, s, OCH_3), 1.43 (9 H, s, $\text{C}(\text{CH}_3)_3$). ^{13}C NMR (75 MHz, CDCl_3 , 20 °C): δ = 156.3, 155.5 (C=O and C-O), 140.2, 126.5 (quat.), 129.8, 128.5 (x2), 127.6, 127.4, 126.8 (x2), 120.9, 112.4 (aromatic CH), 99.6 ($\text{CH}(\text{OCH}_3)_2$), 79.5 ($\text{C}(\text{CH}_3)_3$), 72.0 (CH_2O), 54.6 (OCH_3), 54.1 (CHN), 52.0 (OCH_3),


28.4 (C(CH₃)₃). I.R. (ATR): ν_{max} 3335, 2977, 2933, 2830, 1706, 1604, 1591, 1515, 1491, 1454, 1391, 1366, 1284, 1239, 1164, 1121, 1092, 1070, 1047, 979, 947, 902, 867, 794, 751, 699, 666, 633 cm⁻¹. HRMS (ESI⁺): found 388.2119 [Calcd for C₂₂H₃₀NO₅⁺ (M + H)⁺ 388.2124].

(S)-tert-Butyl (1-(2-(dimethoxymethyl)phenoxy)-propane-2-yl)carbamate 8e.



It was prepared from 4-bromosalicylaldehyde **1b** and Boc-amino alcohol (S) **7e** following the same procedure described for **8a**, but using 1.1 equiv. of **6b** relative to Boc-amino alcohol (S)-**7e**. The isolated yield of **8d** was 60% from **7e**. Chromatography was carried out with PE: AcOEt : CH₂Cl₂ 8:1:1 → 6:1:1. Oil. R_f = 0.37 (PE / AcOEt / CH₂Cl₂ 8:1:1). $[\alpha]_D^{25}$ = -40.4 (c 1.0, CHCl₃). ¹H NMR (300 MHz, CDCl₃, 20 °C): δ = 7.64 (1 H, d, J = 2.4 Hz), 7.38 (1 H, dd, J = 8.7, 2.7 Hz), 6.74 (1 H, d, J = 8.7 Hz), 5.61 (1 H, s, CH(OCH₃)₂), 5.26 (broad s, NH), 4.05 (1 H, broad s, CHNH), 4.01 (1 H, dd, J = 8.9, 2.8 Hz, CHHO), 3.90 (1 H, dd, J = 8.9, 4.3 Hz, CHHO), 3.41 (3 H, s, OCH₃), 3.28 (3 H, s, OCH₃), 1.44 (9 H, s, C(CH₃)₃), 1.31 (3 H, d, J = 6.6 Hz, CH₃CH). ¹³C NMR (75 MHz, CDCl₃, 20 °C): δ = 155.6, 155.3 (C=O and C-O), 132.4, 130.6, 114.0 (aromatic CH), 128.4, 113.3 (quat.), 98.5 (CH(OCH₃)₂), 79.3 (C(CH₃)₃), 72.2 (CH₂O), 54.3 (OCH₃), 52.0 (OCH₃), 45.9 (CHN), 28.4 (C(CH₃)₃), 18.2 (CH₃CH). I.R. (ATR): ν_{max} 3350, 2976, 2933, 2830, 1695, 1595, 1514, 1487, 1457, 1404, 1391, 1365, 1266, 1242, 1164, 1133, 1099, 1053, 980, 912, 875, 854, 806, 781, 752, 734, 677, 657, 645, 616 cm⁻¹. HRMS (ESI⁺): found 404.1075 [Calcd for C₁₇H₂₇BrNO₅⁺ (M + H)⁺ 404.1073].


(R)-tert-Butyl (1-(2-(dimethoxymethyl)phenoxy)-propane-2-yl)carbamate ent-8e.



It was prepared exactly as for **8e**, but starting from **ent-7e**. $[\alpha]_D^{25}$ = +39.9 (c 1.0, CHCl₃). The other spectroscopical data were identical to those of **8e**.

Optimization of Ugi-Joullié reaction to give 10a.

In all cases (except entries 6,9) 1.2 equivalents of acetic acid and 1.2 equivalents of *tert*-butyl isocyanide were used.



Entry	Solvent	Additive	Time	Temp.	Yield % ^a	D.r. ^b
1	MeOH	none	45 h	rt	80	96 : 4
2	CH ₂ Cl ₂	none	38 h	rt	74	90.5 : 9.5
3	CH ₂ Cl ₂	ZnBr ₂ (0.5 equiv.)	45 h	rt	69	94 : 6
4	CH ₂ Cl ₂	ZnBr ₂ (1.0 equiv.)	48 h (incomplete)	rt	51	89:11
5	MeOH	ZnBr ₂ (0.5 equiv.)	48 h (incomplete)	rt	49	96 : 4
6	CH ₂ Cl ₂	Zn(OAc) ₂ (1.2 equiv.) ^c	48 h (largely incomplete)	rt	9	95 : 5
7	THF	none	48 h (incomplete)	rt	29	88 : 12
8	THF	ZnBr ₂ (0.5 equiv.)	48 h (incomplete)	rt	34	95 : 5
9	THF	Zn(OAc) ₂ (1.2 equiv.) ^c	48 h (no reaction)	rt	-	-
10	EtOH	none	48 h (incomplete)	rt	62	92 : 8
11	<i>i</i> BuOH	none	48 h (incomplete)	rt	46	87 : 13

^a Isolated yield of major diastereomer only. ^b Determined by HPLC on the crude product. ^c Zn(OAc)₂ was used instead of AcOH


Typical procedure for the synthesis of Ugi-Joullié adducts: (3*S*,5*R*)-4-Acetyl-3-benzyl-N-(*tert*-butyl)-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepine-5-carboxamide **10a**.

Acetal **8a** (312.4 mg, 778 μmol) was dissolved in CH₂Cl₂ (3.0 mL) and treated with 37% aqueous HCl (640 μL, 7.73 mmol). The mixture was stirred at rt for 5 h. Then it was diluted with CH₂Cl₂, and cautiously treated with 5% aqueous Na₂CO₃ (25 mL). After checking that pH > 9, the two phases were separated, washed with brine, and evaporated to dryness. The resulting crude imine **3a** (oil) was taken up in dry methanol (3.90 mL), and treated with acetic acid (53 μL, 927 μmol), and *tert*-butyl isocyanide (106 μL, 937 μmol). The mixture was stirred at rt for 45 h and evaporated to dryness. It was taken up in AcOEt, washed with saturated aqueous NaHCO₃ (to remove excess carboxylic acid), evaporated, and chromatographed (PE / AcOEt 2:1) to give pure **10a** (237 mg, 80%). The ratio **10a** : **11a** was determined by HPLC on the crude product and resulted = 96:4. HPLC conditions: C6-Phenyl column 150 x 3 mm, 3 μm. Flow: 0.38 ml/min. Temp: 26°C. Eluent: H₂O : CH₃CN 55:45. Detection: UV 220 nm. R_f of **10a**: 13.62. R_f of **11a**: 14.41. Minor diastereomer **11a** was recognized using a MS (ESI) detector.

White solid. R_f = 0.24 (PE / AcOEt 2:1) (R_f of **11a** = 0.31). [α]_D = +10.0 (c 1.06, CHCl₃). M.p. = 119.7-122.0 °C. ¹H NMR (300 MHz, d₆-DMSO, 90 °C): δ = 7.57 (1 H, dd, J = 7.7, 1.6 Hz), 7.36-7.16 (6 H, m), 7.00 (2 H, t, J = 8.2 Hz), 6.47 (1 H, broad s, NH), 5.66 (1 H, broad s, CHC=O), 4.77 (1 H, broad d, J = 11.1 Hz, CHHO), 4.55 (1 H, broad s, CHN), 4.03 (1 H, dd, J = 13.2, 4.8 Hz, CHHO), 2.79 (1 H, dd, J = 13.4, 5.9 Hz, CHHPh), 2.65-2.48 (1 H, m, CHHPh), 2.06 (3 H, s, CH₃C=O), 1.22 (9 H, s, C(CH₃)₃). ¹³C NMR (75 MHz, d₆-DMSO, 90 °C): δ = 169.8, 168.8 (C=O), 155.6 (aromatic C-O), 137.6, 121.4 (quat.),

132.1, 129.6, 128.4 (x2), 127.8 (x2), 125.8, 120.9, 118.8 (aromatic CH), 66.6 (CH₂O), 62.8 (broad) (CHC=O), 57.5 (broad) (CHN), 50.2 (C(CH₃)₃), 36.4 (CH₂Ph), 27.8 (C(CH₃)₃), 21.2 (CH₃C=O). I.R. (ATR): ν_{max} 3410, 3314, 3067, 3034, 2966, 2928, 2870, 1671, 1639, 1607, 1580, 1563, 1509, 1494, 1453, 1416, 1391, 1366, 1352, 1332, 1305, 1288, 1267, 1249, 1224, 1193, 1172, 1157, 1125, 1115, 1086, 1052, 1028, 1007, 973, 937, 908, 885, 871, 862, 827, 802, 752, 731, 719, 700, 665, 644, 631, 616, 603 cm⁻¹. HRMS (ESI⁺): found 381.2171 [Calcd for C₂₃H₂₉N₂O₃⁺ (M + H)⁺ 381.2178].


(3*S*,5*R*)-3-Benzyl-*N*-(cyclohexyl)-4-phenylacetyl-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepine-5-carboxamide 10b.



It was prepared in 65% overall yield from (*S*)-**8a**, phenylacetic acid and cyclohexyl isocyanide, following the typical procedure described for **10a**. Chromatography was carried out with PE / AcOEt / CH₂Cl₂ 5 : 1 : 1. Separation of the two diastereomers was not complete. We obtained fractions with pure **10b** plus some fractions contaminated with little **11b**. The overall yield was 65%. The calculated yield of **10b** is therefore 62%. The d.r. was = 94 : 6 by HPLC of the crude product. Conditions: column Luna C8 150 x 4.6 mm, 5 μ . Flow: 0.8 ml/min. Temp: 25°C. Eluent: H₂O : MeOH 30:70. Detection: UV 220 nm. *R_f* of **10b**: 21.25. *R_f* of **11b**: 20.43. Minor diastereomer **11b** was recognized using a MS (ESI) detector.

White solid. *R_f* = 0.21 (PE / AcOEt / CH₂Cl₂ 5 : 1 : 1) (*R_f* of **11b** = 0.24). [α]_D = +9.0 (c 1.0, CHCl₃). M.p. = 157.8-159.9 °C. ¹H NMR (300 MHz, d₆-DMSO, 90 °C): δ = 7.42 (1 H, broad s), 7.36-7.15 (11 H, m), 7.05-6.95 (2 H, m), 6.80 (1 H, broad d, *J* = 6.6 Hz, NH), 5.72 (1 H, s, CHC=O), 4.75 (1 H, broad d, *J* = 12.3 Hz, CHHO), 4.61 (1 H, broad s, CHN), 4.02 (1 H, dd, *J* = 13.3, 4.6 Hz, CHHO), 3.84 (1 H, d, *J* = 15.6 Hz, CHHC=O), 3.67-3.50 (2 H, m, CHC=O, CHNH), 2.80 (1 H, dd, *J* = 13.2, 6.0 Hz, CHHPh), 2.65-2.48 (1 H, m, CHHPh), 1.80-1.45 (5 H, m, CH₂ cyclohexyl), 1.35-1.05 (5 H, m, CH₂ cyclohexyl). ¹³C NMR (75 MHz, d₆-DMSO, 90 °C): δ = 170.2 168.4 (C=O), 155.6 (broad) (aromatic C-O), 137.5, 135.1, 121.3 (quat.), 132.1, 129.6 (x2), 128.5 (x2), 128.4 (x2), 127.8 (x2), 127.6, 125.83, 125.76, 121.0, 118.7 (aromatic CH), 66.7 (broad) (CH₂O), 65.9 (broad) (CHC=O), 57.3 (broad) (CHN), 47.7 (CHNH), 39.4 (CH₂C=O, hidden by DMSO signal, visible at qHSQC), 36.3 (broad) (CH₂Ph), 31.2 (x2), 24.6, 23.7, 23.6 (CH₂ cyclohexyl). I.R. (ATR): ν_{max} 3271, 3023, 2977, 2940, 2920, 2855, 1656, 1633, 1604, 1582, 1525, 1492, 1451, 1416, 1360, 1343, 1319, 1306, 1289, 1270, 1250, 1222, 1193, 1150, 1115, 1094, 1076, 1060, 1029, 1012, 981, 968, 957, 935, 907, 893, 884, 875, 853, 826, 809, 781, 762, 749, 720, 696, 640, 619 cm⁻¹. HRMS (ESI⁺): found 483.2654 [Calcd for C₃₁H₃₅N₂O₃⁺ (M + H)⁺ 483.2648].


(3*S*,5*R*)-3-Benzyl-4-(2-((benzyloxycarbonyl)amino)acetyl)-*N*-(isopropyl)-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepine-5-carboxamide 10c.



It was prepared in 80% overall yield from (*S*)-**8a**, *N*-benzyloxycarbonyl glycine and isopropyl isocyanide, following the typical procedure described for **10a**. Chromatography was carried out with PE / AcOEt 2 : 1. Separation of the two diastereomers was not complete. We obtained fractions with pure **10c** plus some fractions contaminated with little **11c**. The overall yield was 80%. The calculated yield of **10c** is therefore 74.4%. The d.r. was = 94 : 6 by HPLC of the crude product. Conditions: column Luna C8 150 x 4.6 mm, 5 μ . Flow: 1 ml/min. Temp: 26°C. Eluent: H₂O : CH₃CN 50:50. Detection: UV 220 nm. *R*_f of **10c**: 20.55. *R*_f of **11c**: 21.68. Minor diastereomer **11c** was recognized using a MS (ESI) detector.

White solid. *R*_f = 0.12 (PE / AcOEt 2 : 1) (*R*_f of **11c** = 0.17). [α]_D = -19.7 (c 1.0, CHCl₃). M.p. = 70.0-72.2 °C. ¹H NMR (300 MHz, d₆-DMSO, 90 °C): δ = 7.56 (1 H, d, *J* = 7.5 Hz), 7.40-7.17 (11 H, m), 7.01 (2 H, t, *J* = 7.5 Hz), 7.00-6.90 (1 H, m, NHCH₂), 6.89 (1 H, broad d, *J* = 7.2 Hz, NHCH), 5.66 (1 H, s, CHC=O), 5.08 (2 H, s, PhCH₂O), 4.76 (1 H, broad d, *J* = 12.9 Hz, CHHO), 4.54 (1 H, broad s, CHN), 4.16 (1 H, dd, *J* = 16.6, 5.6 Hz, CHHNH), 4.01 (1 H, dd, *J* = 13.2, 4.5 Hz, CHHO), 3.93-3.77 (2 H, m, CHNH, CHHNH), 2.82 (1 H, dd, *J* = 13.4, 5.1 Hz, CHHPh), 2.62-2.48 (1 H, m, CHHPh), 1.08 (3 H, d, *J* = 6.6 Hz, CH₃), 1.00 (3 H, d, *J* = 6.6 Hz, CH₃). ¹³C NMR (75 MHz, d₆-DMSO, 90 °C): δ = 168.6 168.2 (C=O), 155.7, 155.5 (C=O urethane and aromatic C-O), 137.4, 136.6, 121.1 (quat.), 132.4, 129.6, 128.4 (x2), 127.8 (x2), 127.7 (x2), 127.1, 126.9 (x2), 125.9, 120.9, 118.7 (aromatic CH), 66.0 (broad) (CH₂O), 65.1 (PhCH₂O), 61.6 (broad) (CHC=O), 57.2 (CHN), 42.3 (CH₂NH), 40.8 (CHNH), 36.3 (broad) (CH₂Ph), 21.3 (CH₃). I.R. (ATR): ν_{max} 3410, 3321, 3064, 3031, 2971, 2935, 1715, 1648, 1606, 1581, 1510, 1493, 1453, 1424, 1387, 1366, 1347, 1241, 1220, 1156, 1115, 1084, 1049, 1030, 1010, 929, 912, 892, 871, 826, 797, 749, 697, 658, 638 cm⁻¹. HRMS (ESI⁺): found 516.2490 [Calcd for C₃₀H₃₄N₃O₅⁺ (M + H)⁺ 516.2498].

(3*S*,5*R*)-*N*-(4-Allyloxyphenyl)-3-benzyl-4-(3-bromobenzoyl)-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepine-5-carboxamide 10d.




A solution of *N*-(4-(allyloxy)phenyl)formamide (100 mg, 564 μ mol)⁵ in dry CH₂Cl₂ (0.84 mL) was cooled at 0°C and treated with 161.2, mg (676 μ mol, 1.2 eq.) of Burgess reagent (Methyl *N*-(triethylammoniosulfonyl)carbamate inner salt). The mixture was stirred at 0°C for 3h, then further 66.0 mg (276 μ mol) S9

of Burgess Reagent were added to the mixture. After 10 min. the mixture was allowed to reach room temperature and stirred for 2h. This mixture was then added to a solution of imine **3a** (400 μ mol) in MeOH (1.5 mL), prepared as described above for the synthesis of **10a**. Finally, 112 mg (557 μ mol mmol) of 3-bromobenzoic acid were added at this mixture. The mixture was stirred at room temperature for 48h and then 30 °C overnight. The solvent was evaporated under reduced pressure and the crude product was purified by chromatography (PE: AcOEt 5:1) to give pure **10d** (128.8 mg, 54%). The d.r. was = 93 : 7 by HPLC of the crude product. HPLC conditions: C6-Phenyl column 150 x 3 mm, 3 μ m. Flow: 0.34 ml/min. Temp: 25°C. Eluent: H₂O : CH₃CN 40:60 + 1% CF₃CO₂H. Detection: UV 220 nm. *R_f* of **10d**: 13.33. *R_f* of **11d**: 14.00. Minor diastereomer **11d** was recognized using a MS (ESI) detector. The overall yield, calculated from the d.r., was 58%.

White solid. *R_f* = 0.13 (PE / AcOEt 2 : 1). [α]_D = +57.0 (c 1.0, CHCl₃). M.p. = 148.6-150.7 °C. ¹H NMR (300 MHz, d₆-DMSO, 90 °C): δ = 9.17 (1 H, s, NH), 7.64 (2 H, ddd, *J* = 8.1, 1.8, 1.0 Hz), 7.44-7.18 (9 H, m), 7.10 (1 H, td, *J* = 7.5, 1.2 Hz), 7.05 (1 H, dd, *J* = 8.1, 0.9 Hz), 7.01-6.92 (2 H, m), 6.88 (2 H, d, *J* = 9.0 Hz), 6.02 (1 H, ddt, *J* = 17.2, 10.5, 5.2 Hz, CH=CH₂), 5.81 (1 H, broad s, CHC=O), 5.37 (1 H, dq, *J* = 17.2, 1.6 Hz, CH=CHH), 5.23 (1 H, dq, *J* = 10.5, 1.5 Hz, CH=CHH), 4.95 (1 H, dd, *J* = 12.3, 1.8 Hz, CHHO), 4.53 (2 H, dt, *J* = 5.4, 1.5 Hz, CH₂CH=CH₂), 4.44 (1 H, broad s, CHN), 4.13 (1 H, dd, *J* = 13.0, 4.0 Hz, CHHO), 2.73 (1 H, dd, *J* = 13.2, 7.3 Hz, CHPh), 2.62 (1 H, dd, *J* = 13.2, 8.4 Hz, CHHPh). ¹³C NMR (75 MHz, d₆-DMSO, 90 °C): δ = 169.1 167.4 (C=O), 155.6, 154.4, 138.0, 137.2, 131.2, 121.7, 121.2 (quat.), 133.3 (CH=CH₂), 131.9, 131.7, 130.1, 130.0, 128.5 (x2), 128.3, 127.8 (x2), 125.9, 124.6, 121.8, 121.4 (x2), 119.6, 114.4 (x2) (aromatic CH), 116.5 (CH=CH₂), 68.2 (CH₂CH=CH₂), 68.1 (broad) (CH₂O), 63.4 (broad) (CHC=O), 58.4 (broad) (CHN), 37.0 (broad) (CH₂Ph). I.R. (ATR): ν_{max} 3314, 3062, 2945, 2906, 2026, 1672, 1646, 1606, 1578, 1563, 1509, 1488, 1446, 1414, 1386, 1353, 1330, 1305, 1278, 1256, 1211, 1171, 1148, 1114, 1094, 1085, 1069, 1061, 1027, 1007, 967, 934, 914, 897, 887, 864, 824, 807, 752, 730, 709, 703, 682, 665, 649, 637, 605 cm⁻¹. HRMS (ESI⁺): found 597.1396 [Calcd for C₃₃H₃₀BrN₂O₄⁺ (M + H)⁺ 597.1389].


(3*S*,5*R*)-3-iso-Butyl-*N*-(*tert*-butyl)-4-(phenylacetyl)-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepine-5-carboxamide **10e.**



It was prepared in 57% overall yield from (*S*)-**8b**, phenylacetic acid and *tert*-butyl isocyanide, following the typical procedure described for **10a**. The reaction under these conditions was not complete. Chromatography was carried out with PE / AcOEt 5 : 1. Separation of the two diastereomers was not complete. We obtained fractions with pure **10e** plus some fractions contaminated with little **1e**. The overall yield was 57%. The calculated yield of **10e** is therefore 54%. The d.r. was 96 : 4 by HPLC of the crude product. Conditions: column Luna C8 150 x 4.6 mm, 5 μ . Flow: 0.8 ml/min. Temp: 25°C. Eluent: H₂O : MeOH 30:70 + 1% CF₃CO₂H. Detection: UV 220 nm. *R_f* of **10e**: 18.25. *R_f* of **11e**: 16.23. Minor diastereomer **11e** was recognized using a MS (ESI) detector. Oil. *R_f* = 0.22 (PE / AcOEt 5 : 1) (*R_f* of **11e** = 0.25). [α]_D = +12.2 (c 1.0, CHCl₃). ¹H NMR (300 MHz, d₆-DMSO, 90 °C): δ = 7.26-7.07 (7 H, m), 6.32 (1 H, s, NH), 5.52 (1 H, s, CHC=O), 4.59 (1 H, d, *J* = 12.9 Hz, CHHO), 4.36 (1 H, broad s, CHN), 4.12 (1 H, dd, *J* = 13.2, 5.2 Hz, CHHO), 3.74 (1 H, d, *J* = 15.6 Hz, CHHPh), 3.57 (1 H, d, *J* = 15.6 Hz, CHHPh), 1.51 (1 H, nonuplet, *J* = 6.6 Hz, CH(CH₃)₂), 1.17 (2 H, t, *J* = 6.9 Hz, CH₂*i*Pr), 1.11 (9 H, s, C(CH₃)₃), 0.74 (3 H, d, *J* = 6.6 Hz, CH₃CHCH₃), 0.67 (3 H, d, *J* = 6.6 Hz, CH₃CHCH₃). ¹³C NMR (75 MHz, d₆-DMSO, 90 °C): δ = 170.3 168.7 (C=O), 155.7, 135.2, 121.6 (quat.), 131.6, 129.3, 128.5 (x2), 127.6 (x2), 125.8, 120.8, 118.6 (aromatic CH), 67.6 (CH₂O), 62.3 (broad) (CHC=O), 54.0 (broad) (CHN), 50.2 (CH₂*i*Pr),

39.6 (CH₂Ph), 27.7 (C(CH₃)₃), 24.3 (CH(CH₃)₂), 22.7, 21.2 (CH₃). I.R. (ATR): ν_{max} 3413, 3331, 3063, 3030, 2959, 2930, 2870, 1683, 1644, 1604, 1580, 1508, 1492, 1452, 1411, 1393, 1365, 1348, 1309, 1264, 1248, 1219, 1168, 1144, 1115, 1096, 1076, 1057, 1030, 1004, 957, 869, 823, 804, 758, 721, 695, 634 cm⁻¹. HRMS (ESI⁺): found 423.2641 [Calcd for C₂₆H₃₆N₂O₃⁺ (M + H)⁺ 423.2648].


(3*S*,5*R*)-*N*-(Benzyl)-3-*iso*-propyl-4-(methoxyacetyl)-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepine-5-carboxamide 10f.



It was prepared in 53% yield from (*S*)-**8c**, methoxyacetic acid and benzyl isocyanide, following the typical procedure described for **10a**. However, in this case, the Ugi-Joullié step reaction was carried out at 40°C. Chromatography was carried out with PE / AcOEt 1 : 1, affording a complete separation of the two diastereomers. The overall yield was 56%. The d.r. was = 94 : 6 by HPLC of the crude product. Conditions: column Luna C8 150 x 4.6 mm, 5 μ . Flow: 0.8 ml/min. Temp: 25°C. Eluent: H₂O : MeOH 30:70 + 1% TFA. Detection: UV 220 nm. R_t of **10f**: 6.02. R_t of **11f**: 5.49. Minor diastereomer **11f** was recognized using a MS (ESI) detector.

Oil. R_f = 0.35 (PE / AcOEt 1 : 1) (R_f of **11f** = 0.46). [α]_D = -42.4 (c 1.0, CHCl₃). ¹H NMR (300 MHz, d₆-DMSO, 90 °C): δ = 7.80 (1 H, s, NH), 7.48 (1 H, d, J = 6.6 Hz), 7.31-7.14 (6 H, m), 6.99 (1 H, td, J = 7.5, 1.2 Hz), 6.91 (1 H, dd, J = 8.1, 1.1 Hz), 5.62 (1 H, s, CHC=O), 4.76 (1 H, broad d, J = 12.3 Hz, CHHO), 4.37 (1 H, dd, J = 13.2, 4.8 Hz, CHHO), 4.31 (2 H, broad t, J = 5.4 Hz, CH₂NH), 4.29 (1 H, J = 14.2 Hz, CHHOMe), 4.11 (1 H, broad s, CHN), 4.01 (1 H, J = 14.2 Hz, CHHOMe), 3.31 (3 H, s, CH₃O), 1.59 (d of heptuplets, J = 9.9, 6.6 Hz, CH(CH₃)₃), 0.88 (3 H, d, J = 6.6 Hz, CH₃CHCH₃), 0.75 (3 H, d, J = 6.8 Hz, CH₃CHCH₃). ¹³C NMR (75 MHz, d₆-DMSO, 90 °C): δ = 169.3 (x2) (C=O), 156.0, 138.7, 122.3 (quat.), 131.6, 129.5, 127.5 (x2), 126.4 (x2), 126.0, 121.3, 119.1 (aromatic CH), 70.6 (CH₂OMe), 68.1 (broad) (CH₂O), 62.0 (CHC=O), 59.8 (broad) (CHN), 57.8 (OCH₃), 42.3 (CH₂NH), 28.5 (CH(CH₃)₂), 19.3, 18.8 (CH₃). I.R. (ATR): ν_{max} 3314, 3062, 3031, 2964, 2931, 2873, 2825, 1653, 1605, 1580, 1516, 1493, 1453, 1424, 1390, 1367, 1320, 1248, 1218, 1198, 1156, 1124, 1107, 1080, 1028, 965, 948, 860, 838, 750, 731, 698, 640, 605 cm⁻¹. HRMS (ESI⁺): found 397.2135 [Calcd for C₂₃H₂₉N₂O₄⁺ (M + H)⁺ 397.2127].


(3*S*,5*R*)-*N*-(Cyclohexyl)-3-*iso*-propyl-4-(phenylacetyl)-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepine-5-carboxamide 10g.



It was prepared in 79% yield from (*S*)-**8c**, phenylacetic acid and cyclohexyl isocyanide, following the typical procedure described for **10a**. However, in this case, the Ugi-Joullié step reaction was carried out at rt for 64 h. Chromatography was carried out with PE / CH₂Cl₂ / AcOEt 3 : 1 : 1, affording a complete separation of the two diastereomers. The overall yield was 82%. The d.r. was = 96 : 4 by HPLC of the crude product. Conditions: column Luna C8 150 x 4.6 mm, 5 μ . Flow: 0.8 ml/min. Temp: 25°C. Eluent: H₂O : MeOH 30:70. Detection: UV 220 nm. *R_f* of **10g**: 15.14. *R_f* of **11g**: 13.89. Minor diastereomer **11g** was recognized using a MS (ESI) detector.

White solid. *R_f* = 0.42 (PE / CH₂Cl₂ / AcOEt 3 : 1 : 1). [α]_D = -72.8 (c 1.0, CHCl₃). M.p.: 65.0-67.2 °C. ¹H NMR (300 MHz, d₆-DMSO, 120 °C): δ = 7.39 (1 H, d, *J* = 7.8 Hz), 7.33-7.19 (6 H, m), 6.98 (1 H, t, *J* = 7.5 Hz), 6.89 (1 H, d, *J* = 8.1), 6.78 (1 H, broad s, *NH*), 5.61 (1 H, s, *CHC=O*), 4.63 (1 H, dd, *J* = 12.5, 3.0 Hz, *CHHO*), 4.35 (1 H, dd, *J* = 12.5, 5.5 Hz, *CHHO*), 4.20 (1 H, broad s, *CHN*), 3.86 (1 H, d, *J* = 15.6 Hz, *CHHPh*), 3.71 (1 H, d, *J* = 15.6 Hz, *CHHPh*), 3.63 (1 H, broad m, *CHNH*), 1.83-1.48 (6 H, m, *CH(CH₃)₂* and *CH₂* cyclohexyl), 1.38-1.10 (5 H, m, *CH₂* cyclohexyl), 0.89 (3 H, d, *J* = 6.6 Hz, *CH₃CHCH₃*), 0.75 (3 H, d, *J* = 6.8 Hz, *CH₃CHCH₃*). ¹³C NMR (75 MHz, d₆-DMSO, 90 °C): δ = 171.3, 168.1 (*C=O*), 156.0, 135.4, 123.3 (quat.), 130.8, 129.3, 128.7 (x2), 127.6 (x2), 125.8, 121.4, 119.3 (aromatic CH), 68.6 (*CH₂O*), 62.5 (broad) (*CHC=O*), 60.4 (very broad) (*CHN*), 47.6 (*CHNH*), 39.9 (*CH₂Ph*), 31.43, 31.37, 24.6, 23.7, 23.6 (*CH₂* cyclohexyl), 28.5 (*CH(CH₃)₂*), 19.3, 18.8 (*CH₃*). I.R. (ATR): $\nu_{\max}$ 3418, 3320, 3064, 3031, 2930, 2854, 1647, 1604, 1581, 1510, 1493, 1450, 1408, 1387, 1367, 1348, 1319, 1248, 1217, 1153, 1113, 1080, 1031, 949, 891, 855, 810, 795, 757, 747, 719, 696, 641 cm⁻¹. HRMS (ESI⁺): found 435.2639 [Calcd for C₂₇H₃₅N₂O₃⁺ (*M* + *H*)⁺ 435.2648].


(3*S*,5*R*)-4-(Acetyl)-*N*-(*tert*-butyl)-3-*iso*-propyl-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepine-5-carboxamide **10h.**



It was prepared in 52% yield from (*S*)-**8c**, acetic acid and *tert*-butyl isocyanide, following the typical procedure described for **10a**. The reaction was in this case incomplete and also 6% of starting material was recovered. Chromatography was carried out with CH₂Cl₂ / AcOEt 4 : 1, affording a complete separation of the two diastereomers. The minor diastereomer **11h** was not detected by HPLC-MS or NMR. The d.r. was thus supposed to be > 97 : 3. HPLC conditions: C6-Phenyl column 150 x 3 mm, 3 μ m. Flow: 0.38 ml/min. Temp: 26°C. Eluent: H₂O : CH₃CN 60:40. Detection: UV 220 nm. *R_f* of **10h**: 11.66.

White solid. *R_f* = 0.28 (CH₂Cl₂ / AcOEt 4 : 1). [α]_D = -9.4 (c 0.9, CHCl₃). M.p.: 104.5-107.8 °C. ¹H NMR (300 MHz, d₆-DMSO, 120 °C): δ = 7.46 (1 H, dd, *J* = 7.6, 1.4 Hz), 7.25 (1 H, td, *J* = 8.0, 1.6), 6.98 (1 H, td, *J* = 7.5, 1.1 Hz), 6.90 (1 H, dd, *J* = 8.1, 1.0), 6.62 (1 H, broad s, *NH*), 5.49 (1 H, s, *CHC=O*), 4.68 (1 H, dd, *J* = 12.5, 3.7 Hz, *CHHO*), 4.35 (1 H, dd, *J* = 12.5, 5.8 Hz, *CHHO*), 4.12 (1 H, broad s, *CHN*), 2.10 (3 H, s, *CH₃C=O*), 1.71 (1 H, d of heptuplets, *J* = 9.9, 6.6 Hz, *CH(CH₃)₃*), 1.26 (9 H, s, *C(CH₃)₃*), 0.90 (3 H, d, *J* = 6.6 Hz, *CH₃CHCH₃*), 0.79 (3 H, d, *J* = 6.8 Hz, *CH₃CHCH₃*). ¹³C NMR (75 MHz, d₆-DMSO, 90 °C): δ = 170.3, 168.4 (*C=O*), 155.9, 123.3 (quat.), 130.7, 129.1, 121.2, 119.2 (aromatic CH), 68.4 (*CH₂O*), 63.3 (broad) (*CHC=O*), 59.9 (very broad, barely visible) (*CHN*), 50.1 (*CNH*), 28.4 (*CH(CH₃)₂*), 27.8 (*C(CH₃)₃*), 21.7 (*CH₃C=O*), 19.3, 18.9 (*CH₃*). I.R. (ATR): $\nu_{\max}$ 3332, 2965, 2933, 2874, 1980, 1668, 1640, 1607, 1583, 1529, 1496, 1451, 1413, 1392, 1365, 1346, 1331, 1303, 1289, 1266, 1250, 1218, 1116, 1088, 1041, 979, 945, 900, 890, 858, 841, 812, 755, 746, 689, 654, 631, 621 cm⁻¹. HRMS (ESI⁺): found 333.2176 [Calcd for C₁₉H₂₉N₂O₃⁺ (*M* + *H*)⁺ 333.2178].


(3*R*,5*S*)-4-(3-Bromobenzoyl)-*N*-(cyclohexyl)-3-phenyl-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepine-5-carboxamide 10i.



It was prepared in 86% yield from (*R*)-**8d**, 3-bromoacetic acid and cyclohexyl isocyanide, following the typical procedure described for **10a**. However, in this case, 1.3 equivalents of isocyanide were used. Chromatography was carried out with PE/AcOEt 3:1→AcOEt/MeOH 95:5, affording a complete separation of the two diastereomers. The minor diastereomer **11** was not isolated. An overall yield 89% was calculated on the basis of d.r. The d.r. was = 97 : 3 by HPLC of the crude product. Conditions: column Luna C8 150 x 4.6 mm, 5 μ . Flow: 0.8 ml/min. Temp: 25°C. Eluent: H₂O : MeOH 30:70 + 1% TFA. Detection: UV 220 nm. *R_t* of **10i**: 10.93. *R_t* of **11i**: 11.72. Minor diastereomer **11i** was recognized using a MS (ESI) detector.

White solid. *R_f* = 0.36 (PE/AcOEt 3 : 1). [α]_D = -98.5 (c 1.0, CHCl₃). M.p.: 229.0-231.5 °C. ¹H NMR (300 MHz, d₆-DMSO, 90 °C): δ = 7.61 (1 H, d, *J* = 7.8 Hz), 7.41-7.22 (4 H, m), 7.21-7.05 (6 H, m), 6.95 (1 H, td, *J* = 7.4, 0.9 Hz), 6.71 (1 H, d, *J* = 8.1), 6.65 (1 H, broad d, *J* = 6.6 Hz, *NH*), 5.78 (1 H, broad s, *CHC=O*), 5.44 (1 H, broad s, *CHPh*), 5.03 (1 H, dd, *J* = 13.6, 1.4 Hz, *CHHO*), 4.53 (1 H, dd, *J* = 13.6, 4.0 Hz, *CHHO*), 3.70-3.55 (1 H, broad m, *CHNH*), 1.82-1.47 (5 H, m, *CH₂* cyclohexyl), 1.40-1.05 (5 H, m, *CH₂* cyclohexyl). ¹³C NMR (75 MHz, d₆-DMSO, 90 °C): δ = 169.7, 168.5 (C=O), 155.3, 138.8, 138.1, 121.0, 120.3 (quat.), 132.1, 131.8, 130.0, 129.4, 128.4, 127.2 (x2), 125.9, 125.6 (x2), 124.6, 120.9, 118.9 (aromatic CH), 68.5 (CH₂O), 64.1 (broad) (*CHC=O*), 60.5 (broad) (*CHN*), 48.1 (*CHNH*), 31.1 (x2), 24.5, 23.8, 23.7 (CH₂ cyclohexyl). I.R. (ATR): ν_{max} 3320, 3063, 3028, 2924, 2850, 1663, 1650, 1610, 1581, 1563, 1512, 1490, 1464, 1449, 1414, 1389, 1352, 1332, 1311, 1275, 1249, 1219, 1178, 1148, 1115, 1080, 1046, 1027, 998, 977, 956, 917, 903, 894, 879, 866, 854, 823, 798, 777, 753, 741, 731, 691, 647 cm⁻¹. HRMS (ESI⁺): found 533.1429 [Calcd for C₂₉H₃₀BrN₂O₃⁺ (*M* + *H*)⁺ 533.1440].

(3*S*,5*R*)-4-(3-Acetyl)-7-bromo-*N*-(*tert*-butyl)-3-methyl-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepine-5-carboxamide 10j.




It was prepared in 68% yield from (*S*)-**8e**, acetic acid and *tert*-butyl isocyanide, following the typical procedure described for **10a**. However, in this case, during Ugi-Joullié reaction, after 24 h, additional 0.2 equivalents of isocyanide were added. Chromatography was carried out with PE/AcOEt 2:1→1:1, affording a complete separation of the two diastereomers. The minor diastereomer **11j** was not isolated. An overall yield 71% was calculated on the basis of d.r. The d.r. was = 95 : 5 by HPLC of the crude product. Conditions: column Luna C8 150 x 4.6 mm, 5 μ . Flow: 0.8 ml/min. Temp: 25°C. Eluent: H₂O : MeOH 50:50 + 1% CF₃CO₂H. Detection: UV 220 nm. *R_t* of **10j**: 13.59. *R_t* of **11j**: 12.51. Minor diastereomer **11j** was recognized using a MS (ESI) detector.

White solid. $R_f = 0.30$ (PE/AcOEt 2 : 1). R_f of **11j** = 0.42. $[\alpha]_D = -46.2$ (c 1.0, CHCl_3). M.p.: 180.3-181.8 °C. ^1H NMR (300 MHz, $\text{d}_6\text{-DMSO}$, 90 °C): δ = 7.74 (1 H, d, $J = 2.1$ Hz), 7.39 (1 H, dd, $J = 8.7, 2.5$ Hz), 6.85 (1 H, d, $J = 8.7$ Hz), 6.62 (1 H, broad s, NH), 5.62 (1 H, broad s, CHC=O), 4.85 (1 H, d, $J = 13.0$ Hz, CHHO), 4.45 (1 H, broad quintuplet, $J = 5.9$ Hz, CHCH_3), 4.18 (1 H, dd, $J = 13.0, 4.9$ Hz, CHHO), 2.12 (3 H, s, $\text{CH}_3\text{C=O}$), 1.25 (9 H, s, $\text{C}(\text{CH}_3)_3$), 1.10 (3 H, d, $J = 6.9$ Hz, CH_3CH). ^{13}C NMR (75 MHz, $\text{d}_6\text{-DMSO}$, 90 °C): δ = 169.4, 168.6 (C=O), 154.9, 123.3, 111.6 (quat.), 134.3, 131.9, 120.7 (aromatic CH), 69.5 (CH_2O), 61.6 (broad) (CHC=O), 51.4 (broad) (CHN), 50.3 (CNH), 27.8 ($\text{C}(\text{CH}_3)_3$), 21.1 ($\text{CH}_3\text{=O}$), 16.2 (CH_3CH). I.R. (ATR): ν_{max} 3413, 3336, 2969, 2930, 1685, 1630, 1570, 1514, 1487, 1449, 1418, 1389, 1369, 1335, 1319, 1299, 1281, 1267, 1254, 1221, 1179, 1146, 1125, 1106, 1090, 1066, 1042, 1000, 962, 929, 903, 877, 823, 766, 740, 709, 689, 659, 624 cm^{-1} . HRMS (ESI+): found 383.0974 [Calcd for $\text{C}_{17}\text{H}_{24}\text{BrN}_2\text{O}_3^+$ ($\text{M} + \text{H}$) $^+$ 383.0970].

(3*R*,5*S*)-4-(3-Acetyl)-7-bromo-*N*-(*tert*-butyl)-3-methyl-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepine-5-carboxamide *ent*-10j.

It was prepared exactly as for the enantiomer **10j**. $[\alpha]_D = +44.9$ (c 1.0, CHCl_3). All the other data were identical to those of the enantiomer.


(3*S*,5*R*)-7-Bromo-4-(5-chlorothiophene-2-carbonyl)-*N*-isopropyl-3-methyl-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepine-5-carboxamide **10k.**



It was prepared in 60% yield from (*S*)-**8e**, 5-chloro-2-thiophenecarboxylic acid and isopropyl isocyanide, following the typical procedure described for **10a**. However, in this case, for the Ugi-Joullié reaction, 1.4 equivalents of isocyanide were used. Chromatography was carried out with PE/AcOEt 4:1→3:1. The minor diastereomer **11k** was not isolated. The overall yield was calculated to be 63% on the basis of d.r. The d.r. was = 95 : 5 by HPLC of the crude product. Conditions: column Luna C8 150 x 4.6 mm, 5 μ . Flow: 0.8 ml/min. Temp: 25 °C. Eluent: H_2O : MeOH 50:50. Detection: UV 220 nm. R_t of **10k**: 16.27. R_t of **11k**: 15.68. Minor diastereomer **11k** was recognized using a MS (ESI) detector.

White solid. $R_f = 0.33$ (PE/AcOEt 4 : 1). $[\alpha]_D = -71.3$ (c 1.0, CHCl_3). M.p.: 166.8-169.0 °C. ^1H NMR (300 MHz, CDCl_3 , 20 °C): δ = 7.41 (1 H, dd, $J = 8.7, 2.4$ Hz), 7.22 (1 H, d, $J = 2.3$ Hz), 7.17 (1 H, d, $J = 3.9$ Hz), 6.90-6.85 (2 H, m), 5.63 (1 H, broad s, CHC=O), 5.49 (1 H, broad s, NH), 4.63 (1 H, d, $J = 13.5$ Hz, CHHO), 4.70-4.58 (1 H, m, CHCH_3), 1.31 (3 H, d, $J = 6.8$ Hz, CH_3CH), 1.12 (3 H, d, $J = 6.6$ Hz, CH_3CHCH_3), 1.10 (3 H, d, $J = 6.6$ Hz, CH_3CHCH_3). ^{13}C NMR (75 MHz, CDCl_3 , 20 °C): δ = 168.8, 164.6 (C=O), 155.5, 135.7, 134.6, 122.1, 113.7 (quat.), 134.1, 133.8, 128.6, 126.2, 121.9 (aromatic CH), 70.2 (CH_2O), 64.4 (CHC=O), 53.9 (CHN), 42.5 (CHNH), 22.4, 22.3 (CH_3) $_2\text{CH}$, 16.8 (CH_3CH). I.R. (ATR): ν_{max} 3283, 3094, 2977, 2933, 2876, 1657, 1623, 1514, 1486, 1434, 1386, 1344, 1316, 1277, 1251, 1220, 1186, 1145, 1129, 1107, 1059, 998, 951, 933, 874, 859, 840, 771, 743, 688 cm^{-1} . HRMS (ESI+): found 471.0156 [Calcd for $\text{C}_{19}\text{H}_{21}\text{BrClN}_2\text{O}_3\text{S}^+$ ($\text{M} + \text{H}$) $^+$ 471.0145].


(3*S*,5*R*)-7-Bromo-4-(5-chlorothiophene-2-carbonyl)-*N*-isopropyl-3-methyl-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepine-5-carboxamide **10I.**



Acetal **8e** (395.4 mg, 976 μmol) was dissolved in CH_2Cl_2 (3.7 mL) and treated with 37% aqueous HCl (808 μL , 9.67 mmol). The mixture was stirred at rt for 5 h. Then it was diluted with CH_2Cl_2 , and cautiously treated with a solution of Na_2CO_3 (765 mg, 7.21 mmol) in water (16.0 mL). After checking that pH > 9, the two phases were separated, washed with brine, and evaporated to dryness. The resulting crude imine **3e** (yellow oil) (197.5 mg) was taken up in dry methanol (4.75 mL), and treated with *tert*-butyl isocyanide (131 μL , 1.15 mmol) and with 3-((*tert*-butyldimethylsilyl)oxy)propanoic acid (252 mg, 1.15 mmol). The mixture was stirred at rt for 24 h. Then further *tert*-butyl isocyanide (21 μL , 0.25 mmol) were added. After stirring for 24 h more, the mixture was evaporated to dryness and chromatographed (PE / AcOEt 5:1) to give pure **10I** (284 mg, 54%). The minor diastereomer **11I** was not isolated. The ratio **10I** : **11I** was determined by HPLC on the crude product and resulted = 95:5. HPLC conditions: column Luna C8 150 x 4.6 mm, 5 μ . Flow: 0.8 ml/min. Temp: 25°C. Eluent: H_2O : MeOH 50:50 + 1% $\text{CF}_3\text{CO}_2\text{H}$ up to 20 minutes. Then 100% MeOH + 1% $\text{CF}_3\text{CO}_2\text{H}$. Detection: UV 220 nm. R_t of **10I**: 20.82. R_t of **11I**: 20.45. Minor diastereomer **11I** was recognized using a MS (ESI) detector. The overall yield was calculated to be 57% on the basis of d.r.

Oil. R_f = 0.33 (PE/AcOEt 5 : 1). $[\alpha]_D^{25} = -23.0$ (c 1.0, CHCl_3). ^1H NMR (300 MHz, d_6 -DMSO, 90 °C): δ = 7.72 (1 H, d, J = 2.5 Hz), 7.39 (1 H, dd, J = 8.7, 2.5 Hz), 6.85 (1 H, d, J = 8.7 Hz), 6.57 (1 H, broad s, NH), 5.64 (1 H, broad s, $\text{CHC}=\text{O}$), 4.82 (1 H, d, J = 13.1 Hz, CHHO), 4.47 (1 H, broad quintuplet, J = 6.1 Hz, CHCH_3), 4.18 (1 H, dd, J = 13.1, 4.9 Hz, CHHO), 3.64 (2 H, t, J = 6.4 Hz, CH_2OSi), 2.55 (1 H, dt, J = 15.6, 7.2 Hz, $\text{CHHC}=\text{O}$), 2.37 (1 H, dt, J = 15.6, 7.2 Hz, $\text{CHHC}=\text{O}$), 1.77 (2 H, quintuplet, J = 6.9 Hz, $\text{CH}_2\text{CH}_2\text{OSi}$), 1.25 (9 H, s, $\text{C}(\text{CH}_3)_3$), 1.11 (3 H, d, J = 6.8 Hz, CH_3CH), 0.89 (9 H, s, $\text{SiC}(\text{CH}_3)_3$), 0.05 (6 H, s, $(\text{CH}_3)_2\text{Si}$). ^{13}C NMR (75 MHz, d_6 -DMSO, 90 °C): δ = 171.7, 168.6 ($\text{C}=\text{O}$), 155.0, 123.4, 111.6 (quat.), 134.2, 131.9, 120.6 (aromatic CH), 69.4 (CH_2O), 61.4 (CH_2OSi), 61.2 (broad) ($\text{CHC}=\text{O}$), 51.1 (CHN), 50.2 (CNH), 28.4 ($\text{CH}_2\text{C}=\text{O}$), 27.8 ($\text{C}(\text{CH}_3)_3$, $\text{CH}_2\text{CH}_2\text{OSi}$), 25.3 ($\text{SiC}(\text{CH}_3)_3$), 17.3 ($\text{SiC}(\text{CH}_3)_3$), 16.2 (CH_3CH), -5.9 ($(\text{CH}_3)_2\text{Si}$). I.R. (ATR): ν_{max} 3418, 3344, 2956, 2929, 2857, 1686, 1625, 1538, 1507, 1486, 1472, 1462, 1454, 1412, 1393, 1365, 1323, 1273, 1250, 1235, 1181, 1124, 1100, 1060, 1005, 968, 939, 834, 775, 752, 679, 664, 626, 612 cm^{-1} . HRMS (ESI+): found 541.2103 [Calcd for $\text{C}_{25}\text{H}_{42}\text{BrN}_2\text{O}_4\text{Si}^+$ ($\text{M} + \text{H}$)⁺ 541.2097].

HPLC conditions for analysis of the diastereomeric ratio of 10m and 11m.



Column Luna C8 150 x 4.6 mm, 5 μ . Flow: 0.8 ml/min. Temp: 25°C. Eluent: H₂O : MeOH 90:10 + 1% CF₃CO₂H up to 20 minutes. Then 100% MeOH + 1% CF₃CO₂H. Detection: UV 220 nm. R_t of **10m**: 17.93. R_t of **11m**: 18.58. The ratio was 90 : 10 (**11m** : **10m**).

HPLC conditions for analysis of the enantiomeric composition of 10j, 11j, *ent*-10j, and *ent*-11j.

Column: Chiral Pak AD 250 x 4, 6 μ m. Flow: 0.8 ml/min. Temp: 25°C. Eluent: hexane : isopropanol 97:3. Detection: DAD (chromatograms are reported at 220 nm). R_t of **10j**: 28.24. R_t of **11j**: 24.31. R_t of *ent*-**10j**: 32.27 R_t of *ent*-**11j**: 29.43.


4-((*tert*-Butyldimethylsilyl)oxy)butanoic acid 12

γ -Butyrolactone (0.763 mL, 10.0 mmol) was dissolved in a solution of NaOH (451 mg, 11.3 mmol) in MeOH (10.0 mL). The mixture was stirred at room temperature for 2 h. It was then evaporated and the crude product (1.2043 g) was taken up in dry DMF (20.0 mL). The mixture was cooled to 0°C and then *tert*-butyldimethylchlorosilane (3.299 g, 21.9 mmol) and imidazole (2.257 g, 33.1 mmol) were added. The mixture was stirred overnight at room temperature. It was diluted with PE / Et₂O 1:1 and washed with water. The organic phases were dried over Na₂SO₄, filtered and evaporated under reduced pressure at low temperature (the rotavapor bath was kept near 0°C). The resulting colourless oil (4.206 g) was taken up with a mixture of water (30.0 mL), MeOH (10.0 mL), THF (10.0 mL), and treated with K₂CO₃ (2.767g, 20.0 mmol). The resulting mixture was stirred at room temperature overnight. It was then concentrated to remove most MeOH and THF, diluted with Et₂O and extracted with water. The aqueous phase was acidified to pH = 4 with HCl 1M and extracted with Et₂O. The organic phases were dried over Na₂SO₄, filtered and evaporated under reduced pressure. The desired product (1.4773 g, 68%) was obtained as a colourless oil and used as such without any purification.

1. K. Jedrzejczak, P. Hrynczyszyn, M. Szczesio, J. Artym, T. Jastrzabek, M. Kocieba, M. Glowka, K. Huben, I. Kochanowska, M. Zimecki, J. Zabrocki, S. Jankowski and B. Kolesinska, *Bioorg. Med. Chem.*, 2017, **25**, 4265-4276.
2. S. K. Reddy Guduru, S. Chamakuri, I. O. Raji, K. R. MacKenzie, C. Santini and D. W. Young, *J. Org. Chem.*, 2018, **83**, 11777-11793.
3. A. Del Vecchio, F. Caille, A. Chevalier, O. Loreau, K. Horkka, C. Halldin, M. Schou, N. Camus, P. Kessler, B. Kuhnast, F. Taran and D. Audisio, *Angew. Chem., Int. Ed.*, 2018, **57**, 9744-9748.
4. A. L. Braga, D. S. Ludtke, M. W. Paixao, E. E. Alberto, H. A. Stefani and L. Juliano, *Eur. J. Org. Chem.*, 2005, 4260-4264.
5. C. Lambruschini, A. Basso, L. Moni, A. Pinna, R. Riva and L. Banfi, *Eur. J. Org. Chem.*, 2018, 5445-5455.

HPLC and NMR determination of enantiomeric excesses and diastereomeric ratios

HPLC of crude 10a + 11a after Ugi-Joullié reaction




Area Percent Report


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	13.623	VV	0.2297	6410.38281		428.97720	95.7331
2	14.410	VB	0.2373	285.71570		18.03100	4.2669



HPLC of crude 10a + 11a after epimerization promoted by KOH




Area Percent Report


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	13.704	MF	0.2605	4760.31543		304.53952	32.6104
2	14.485	FM	0.2677	9837.21387		612.36823	67.3896



HPLC of crude 10b + 11b




Area Percent Report


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area %s	Height [mAU]	Area %
1	20.427	MF	0.3592	333.90381	15.49456	5.5446	
2	21.249	FM	0.3614	5688.26855	262.29486	94.4554	



HPLC of crude 10c + 11c




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs


Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area %s	Height [mAU]	Area %
1	20.550	BV	0.4486	3527.66724	122.85065	94.3224	
2	21.681	VB	0.4790	212.34320	6.94468	5.6776	

Totals : 3740.01044 129.79533



HPLC of crude 10d + 11d




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU*s	Height [mAU]	Area %
1	13.334	MF	0.2392	4715.04932	328.57242	92.8950
2	14.003	FM	0.2420	360.62830	24.84063	7.1050

HPLC of crude 10e + 11e





Area Percent Report


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU*s	Height [mAU]	Area %
1	16.232	MM	0.2911	172.34360	9.86690	4.0155
2	18.247	MM	0.3363	4119.61475	204.16066	95.9845



HPLC of crude 10f + 11f




```


=====
                        Area Percent Report
=====
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	5.486	FM	0.1689	185.27025	18.28515	5.7318
2	6.020	MF	0.1627	3047.03931	312.05853	94.2682



HPLC of crude 10g + 11g




```


=====
                        Area Percent Report
=====
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	13.886	PP	0.2689	159.05804	9.19113	3.5708
2	15.137	VB	0.2858	4295.31494	235.29900	96.4292



HPLC of crude 10h




Area Percent Report


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	11.661	VV	0.2277	7715.28467		505.11163	100.0000



HPLC of crude 10i + 11i




Area Percent Report


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	10.929	MM	0.1538	7710.82275		835.43097	96.9686
2	11.719	MM	0.1742	241.05122		23.06897	3.0314



HPLC of crude 10j + 11j




Area Percent Report


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	12.507	MM	0.1441	237.96765		27.53019	4.8268
2	13.586	MM	0.1313	4692.12158		595.68738	95.1732



HPLC of crude 10k + 11k




Area Percent Report


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	15.676	MM	0.1331	201.78844		25.26794	5.2093
2	16.267	MM	0.1256	3671.84375		487.42706	94.7907



HPLC of crude 10I + 11I




Area Percent Report


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	20.450	MM	0.1180	167.12010		23.60336	5.1841
2	20.819	MM	0.1119	3056.55444		455.33575	94.8159



HPLC of crude 11m + 10m (after reaction of 10I with TBAF)




Area Percent Report


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	17.929	MM	0.1190	3121.02319		437.27203	90.2711
2	18.577	MM	0.1171	336.36569		47.86787	9.7289



HPLC of chiral stationary phase of crude **11j** + **10j** after Ugi-Joullié reaction




Area Percent Report


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=220,8 Ref=450,50

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	24.459	MM	0.8556	210.09351	4.09243	5.3066
2	28.248	MM	0.9804	3749.00391	63.73133	94.6934



HPLC of chiral stationary phase of **11j** + **10j** after epimerization (partially enriched in **11j** by chromatography).




Area Percent Report


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=220,8 Ref=450,50


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	24.314	MM	0.8527	5750.31738	112.39552	85.2836
2	28.235	MM	0.9750	992.26495	16.96245	14.7164




HPLC of chiral stationary phase of pure **ent-10j** isolated by chromatography after Ugi-Joullié reaction.



HPLC of chiral stationary phase of **ent-11j** isolated by prep TLC after Ugi-Joullié reaction (impure of some starting imine **3e**).




Conformational analysis of compounds 13 and 14



This study was carried out Using the commercial software ChemBio3D Ultra and the MOPAC (PM3) interface. First of all we have searched for all the local minima of the parent compound

This parent compound gives rise to three conformations with similar energy. One of them resembles a chair, while the second one resembles a twist and the third one a boat. Thus, here we conventionally adopt these three terms. Obviously, each of these three conformations exist in two possible enantiomeric forms, which are in equilibrium.

A notable difference between them is that in the chair and twist conformations the axial hydrogen at C-5 is located on the same side of the median plane than C-2 and C-3. On the contrary, in the boat, they are opposite.



When passing to the real compound, the two conformations of each type become diastereomeric. Thus, we must consider 6 different conformations for each diastereomer. We have searched for the absolute minimum for each of them. According to the heat of formation found, the ones evidenced in yellow are more likely

Conformations of cis compound (14)						
Number	Type	Heat of formation (Kcal/mol)	Position of H-5	Position of H-3	Distance between H-5 and H-3 (Å)	Dihedral angles between H-2 and H-3
1	Chair	-60.49	axial	axial	2.31	178, 61
2	Twist	-59.48	axial	axial	2.45	91, 29

3	Boat	-59.39	equatorial	axial	2.50	153, 32
4	Chair	-57.76	equatorial	equatorial	4.09	68, 52
5	Twist	-57.15	equatorial	equatorial	4.11	175, 55
6	Boat	is converted to other conformations	axial	equatorial	-	-

Conformations of <i>trans</i> compound (13)						
Number	Type	Heat of formation (Kcal/mol)	Position of H-5	Position of H-3	Distance between H-5 and H-3 (Å)	Dihedral angles between H-2 and H-3
1	Chair	-60.06	equatorial	axial	3.61	67, 53
2	Chair	-59.79	axial	equatorial	3.68	174, 65
3	Twist	-59.55	axial	equatorial	3.61	149, 28
4	Twist	-58.73	equatorial	axial	3.73	97, 24
5	Boat	is converted to other conformations	axial	axial	-	-
6	Boat	is converted to other conformations	equatorial	equatorial	-	-

From these results, it is clear that in general, as expected, conformations that place H-3 and/or H-5 in axial position are favoured. Obviously this means that the substituents at C-5 and/or at C-3 are equatorial. Therefore, the lower energy is obtained for the chair conformation of the *cis* compound, where both hydrogens are axial.


In any case, the differences in heat of formation among the best three conformations of both isomers is too scarce to allow us to draw conclusion on the preferred one.

However, from the data in the tables, it is evident that no conformation of *trans* isomer may be able to give a nOe between H-3 and H-5. On the contrary, the best three conformations of *cis* compound can. NOESY experiments have shown that only the amine derived from the minor (kinetically unfavoured) diastereomer of the Ugi-Joullié reaction gives this nOe. We thus think that this is a proof of the configurational assignment.

Unfortunately, we are not able to measure precisely both J between H-3 and H-2, because one of the diastereotopic H-2 falls very near to H-3 in both isomers. These coupling constants could have given an useful information regarding the stereochemical equilibria, because, as can be seen from the tables, the dihedral angles are quite different among them.

Conformational analysis of imine 3e

Imine **3e** exists in just two half-chair conformations depicted below. The one on the left has the methyl substituent in axial position. The conformation on the right is more stable by about 0.80 Kcal/mol, according to MOPAC - PM3. In both conformations the C=N bond is coplanar to the benzene ring, and the face *trans* to the substituent is less encumbered.



Conformational analysis of amides 10j-11j


This study was carried out Using the commercial software ChemBio3D Ultra and the MOPAC (PM3) interface.

As for the amines **13** and **14**, there are three types of conformations. One of them resembles a chair, while the second one resembles a twist and the third one a boat. Thus, here we conventionally adopt these three terms. Obviously, each of these three conformations exist in two possible diastereomeric forms, which are in equilibrium.

For the *cis* compound **11j**, two conformations clearly emerge as the most stable ones:

- Conformation **A** is a twist where the CONH*t*Bu group is axial and the methyl equatorial. Heat of formation = –99.50 Kcal/mol
- Conformation **B** is a half-chair with the two substituents in axial position. Heat of formation = –98.86 Kcal/mol


CONFORMATIONS OF *CIS* COMPOUND 11j



For the *trans* compound **10j**, two conformations clearly emerge as the most stable ones:

- Conformation **A** is a twist where the CONH*t*Bu group is axial and the methyl axial. Heat of formation = –98.45 Kcal/mol
- Conformation **B** is a half-chair where the CONH*t*Bu group is axial and the methyl equatorial. Heat of formation = –98.29 Kcal/mol

CONFORMATIONS OF *TRANS* COMPOUND **10j**



From these calculations, it is clear that the CONH*t*Bu group prefers an axial position. The *cis* compound seem to be more stable, as demonstrated experimentally by the equilibration under base catalysis.

¹H and ¹³C NMR spectra of all new compounds

